The crystal-engineering strategy was intended to produce a new crystalline phase of berberine, a natural-product medicine associated with antimicrobial properties. Hydrothermal screening experiments yielded the berberine–2-sulfobenzoate salt, and diffraction and thermal analysis supported successful formation of the intended material. The structural investigation found no classic hydrogen bonds within the reported salt system.

Instead, weak C–H···O contacts stabilize the interaction between berberine and 2-sulfobenzoate, while a strong dimeric intermolecular hydrogen bond forms between two 2-sulfobenzoate molecules. Spectroscopic observations showed that vibrational modes in the berberine–2-sulfobenzoate salt shifted relative to the modes of the individual components, with the change evident in the Raman spectra. The researchers interpreted these shifts in conjunction with the crystal structure and computational results, showing that salt formation alters the molecular environment experienced by berberine and 2-sulfobenzoate.

For the density functional calculations, they selected a 1:2 berberine–2-sulfobenzoate system so that the model would cover a larger number of intermolecular hydrogen bonds. The modeled system was examined with quantum theory of atoms in molecules and reduced-gradient density analysis to interpret the strength and type of the molecular interactions, while natural bond orbital analysis was used to assess the stability of the system. The calculations also produced molecular electrostatic potential surfaces for berberine, 2-sulfobenzoate and the salt system, identifying regions associated with electrophilic, nucleophilic and neutral behavior.

Frontier molecular orbital and global-descriptor calculations indicated that the modeled berberine–2-sulfobenzoate salt was more chemically reactive than berberine alone. Molar refractivity was used to characterize drug-likeness behavior, and the authors described the combined evidence as confirmation of a new berberine salt with improved physicochemical properties. These reactivity and drug-likeness results are properties predicted or modeled computationally; the study does not establish clinical advantages for the salt.

The research is a laboratory synthesis and solid-state characterization of a crystalline material rather than a clinical investigation of its effects in people.

Subject of Research: Experimental and quantum-chemical characterization of a crystalline berberine–2-sulfobenzoate salt

Article Title: Synthesis, crystal structure, and characterization of a new crystalline berberine–2-sulfobenzoate salt, integrating vibrational spectroscopy and quantum chemical investigation

Article References: Srivastava, D. A., Prajapati, P., Shimpi, M. R., & Tandon, P. (2026). Synthesis, Crystal Structure and Characterization of a New Crystalline Berberine-2-Sulfobenzoate Salt, Integrating Vibrational Spectroscopy and Quantum Chemical Investigation. Frontiers in Chemistry, 14, 1971429. https://doi.org/10.3389/fchem.2026.1971429

Image Credits: AI Generated

DOI: 10.3389/fchem.2026.1971429

Keywords: berberine, 2-sulfobenzoate, crystal synthesis, hydrogen bonding, vibrational spectroscopy, Raman spectroscopy, density functional theory, quantum chemistry, molecular reactivity, physicochemical properties, Synthesis, crystal

The trial was conducted at Peking Union Medical College Hospital in Beijing between 2020 and 2021. After a two-week run-in, participants were randomly assigned in a 1:1 ratio to berberine plus standard coronary disease therapy or standard therapy alone. The berberine dose was increased in three stages: 100 mg taken orally three times daily for approximately four weeks, then 200 mg three times daily for approximately four weeks, and finally 300 mg three times daily for approximately four weeks. Investigators monitored adherence with pill counts at three follow-up visits, and no participant fell below the prespecified 80% adherence threshold. One participant in the berberine group voluntarily withdrew before the final visit, leaving 11 participants with final clinical measurements in that group and 11 in the standard-therapy group.

Investigators assessed endothelial function using brachial flow-mediated dilation, with image analysts blinded to treatment assignment. Flow-mediated dilation increased numerically in the berberine group, from 6.7% to 9.7%, and the reported comparison did not meet the threshold for statistical significance at p = 0.07. The authors described the vascular result as a directional improvement rather than a demonstrated effect. The strongest lipid signal involved LDL cholesterol, which declined from 1.74 to 1.55 mmol/L with berberine plus standard therapy and from 2.33 to 2.01 mmol/L with standard therapy alone. A significant group-by-time interaction indicated a greater relative reduction in the berberine group, with a between-group difference at follow-up of p = 0.028. Total cholesterol showed only a marginal group-by-time interaction, so the LDL result was not accompanied by equally clear changes across the full lipid profile.

Triglycerides fell in the berberine group, while apolipoprotein B showed a similar direction of change that did not reach statistical significance. Several inflammatory mediators also decreased between baseline and week 12 in participants receiving berberine: interleukin-1α, interleukin-17, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β and vascular endothelial growth factor. These were within-group observations, so the study does not establish that every decline was caused by berberine. High-sensitivity C-reactive protein declined in both groups, and the paper did not establish a significant between-group difference in that measure. Self-reported constipation assessment scale scores improved in the berberine group, whereas Bristol stool form scores showed no significant difference.

Shotgun metagenomic sequencing showed that berberine was associated with a broad restructuring of the fecal microbiome. The researchers sequenced 68 stool samples and assembled a catalog of 3,094,494 non-redundant microbial genes. Community diversity increased in the berberine group, while microbial community structure differed between baseline and follow-up within that group and between the groups at week 12. Forty-three species changed in relative abundance after treatment, and 17 were classified as berberine-responsive taxa after correction for multiple comparisons. Several organisms declined, including Megasphaera micronuciformis, Megasphaera elsdenii, a Clostridiales bacterium and an Azospirillum species, while Ruminococcus, Roseburia and Anaerostipes hadrus increased. The abundance of M. micronuciformis was negatively correlated with total cholesterol, lipoprotein(a) and C-reactive protein, although these correlations do not demonstrate that the bacterium caused the lipid differences.

The microbial response also involved organisms associated with fermentation and short-chain fatty acid production. Roseburia and Ruminococcus are capable of converting dietary polysaccharides or oligosaccharides into short-chain fatty acids, while Flavonifractor plautii and Eubacterium ventriosum, also associated with short-chain fatty acid production, increased in the combined berberine and standard-therapy group but declined in the standard-therapy group. Targeted fecal metabolomics detected a significant rise in butyric acid, from a median of 11.5 at baseline to 21.3 at week 12, with p = 0.04, and a smaller increase in isobutyric acid, from a median of 1.1 to 1.4, with p = 0.037. Acetic acid showed an upward trend during the middle of treatment before declining to a level only marginally above baseline. Gene profiles were consistent with this shift: pathways for acetate formation became progressively enriched, and the abundance of the but gene, which encodes an enzyme involved in terminal butyrate production, increased significantly after berberine treatment.

Berberine was particularly associated with changes in microbial aromatic amino acid catabolism rather than a simple increase in the amino acid precursors phenylalanine and tyrosine. Fecal L-dopa rose to 3.67 in the berberine group at follow-up, compared with 1.05 in the standard-therapy group, in a significant group-by-time interaction. L-arginine, 3-hydroxyphenylacetic acid and phenylpropionic acid followed a similar berberine-enriched pattern, with the reported follow-up L-arginine values being 22.6 and 9.8 in the berberine and standard-therapy groups, respectively. By contrast, tyrosine and L-tryptophan increased over time regardless of berberine exposure. The investigators interpreted those shared changes as a trajectory associated with standard therapy rather than a berberine-specific response.

A gene-level analysis offered a possible explanation for the metabolite shifts. The abundance of the microbial dopamine β-monooxygenase gene correlated with fecal L-dopa, the porA gene correlated with phenylacetic acid and the acdA gene correlated with phenylpropionic acid, with reported correlation coefficients of 0.6 to 0.7. Seventeen KEGG modules changed appreciably after berberine treatment, including pathways associated with tyrosine, phenylacetate, phenylalanine and tryptophan metabolism. The intervention increased several downstream products without a comparably clear rise in their upstream substrates. This pattern is consistent with the authors’ interpretation that berberine remodels microbial metabolic capacity, but the trial did not directly test whether those changes mediated the clinical outcomes.

Some fecal metabolites were statistically associated with circulating lipids, including L-dopa, hydroxyphenyl lactic acid, L-phenylalanine and imidazole propionic acid. These are associations within a small cohort, not evidence that any metabolite caused a lipid change. The authors noted that previous research had linked phenylpropionic acid to intestinal epithelial barrier function and aryl hydrocarbon receptor signaling, while L-dopa has a context-dependent relationship with cardiovascular biology. They also proposed that the observed fecal L-dopa enrichment might reflect a local gut–vascular axis, but acknowledged that dedicated tracer studies would be needed to determine whether the compound reaches the circulation or acts directly on host tissues. Berberine’s low oral bioavailability makes interactions with the gut microbiota plausible, yet direct effects on host tissues remain possible as well.

The trial is best understood as exploratory rather than definitive. Its two groups differed substantially in age and sex distribution, and potential residual confounding from smoking, alcohol consumption, diet and physical activity could not be fully excluded despite clinical annotation. Missing observations for some clinical parameters also prevented robust between-group comparisons of certain outcomes, while the limited cohort restricted analysis of downstream metabolites. The parallel design helped account for shared coronary disease secondary-prevention therapies, but the findings do not establish that berberine prevents heart attacks, improves survival or should replace established secondary prevention. The results instead identify measurable changes in LDL cholesterol, vascular function, inflammation and the gut ecosystem in a specific group of stable coronary artery disease patients after percutaneous coronary intervention, while leaving their clinical meaning for further investigation.

Subject of Research: Pilot randomized trial of berberine, vascular function, lipids, gut microbiota and fecal metabolites in stable coronary artery disease after percutaneous coronary intervention.

Article Title: Berberine improves lipid levels, vascular function, and gut microbial-dependent metabolites in stable coronary artery disease patients

Article References: Liu, H., Feng, S., Tang, M., Sun, J., Tian, R., & Zhang, S. (2026). Berberine improves lipid levels, vascular function, and gut microbial-dependent metabolites in stable coronary artery disease patients. Frontiers in Nutrition, 13, Article 1945710. https://doi.org/10.3389/fnut.2026.1945710

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1945710

Keywords: Berberine, Coronary artery disease, Gut microbiome, Short-chain fatty acids, LDL cholesterol, Endothelial function, Metabolomics, Metagenomics, Inflammation, Clinical trial, improves, lipid

A recent narrative review published in the journal Pharmacia critically evaluates the current evidence regarding three specific complementary nutritional supplements: vitamin D, berberine, and chromium. The study synthesized mechanistic, preclinical, observational, and clinical data from publications between 2010 and March 2026 to provide an integrated comparative evaluation of these compounds. Unlike previous reviews that often examined these supplements in isolation, this research offers a unified framework to understand how they influence insulin resistance through distinct but potentially complementary mechanisms. The findings suggest that while these supplements show promise, their clinical efficacy is highly dependent on individual metabolic phenotypes and baseline nutritional status.

Vitamin D has attracted significant attention due to its involvement in vitamin D receptor-mediated regulation of insulin signaling and pancreatic beta-cell function. Observational studies consistently demonstrate an inverse association between circulating vitamin D levels and markers of insulin resistance, such as HOMA-IR and fasting glucose. In prediabetic animal models, vitamin D3 supplementation has been shown to improve glucose regulation by modulating key signaling pathways like IRS-1 and PPARγ. However, clinical trial data remains heterogeneous, with benefits appearing most evident in individuals who have baseline vitamin D deficiency, obesity, or elevated cardiometabolic risk. The sequestration of vitamin D within adipose tissue in obese individuals may partly explain the reduced bioavailability and the variable responses observed in clinical settings.

Berberine, a plant-derived isoquinoline alkaloid, is perhaps the most extensively investigated nutraceutical in the context of insulin resistance. Its primary mechanism involves the activation of AMP-activated protein kinase (AMPK), a critical regulator of cellular energy metabolism. Through this pathway, berberine enhances peripheral glucose uptake, suppresses hepatic gluconeogenesis, and promotes fatty acid oxidation. Clinical studies have reported favorable effects on fasting glucose, HbA1c, triglycerides, and inflammatory markers in patients with metabolic syndrome and type 2 diabetes. Despite its promising metabolic profile, berberine is limited by low oral bioavailability due to poor intestinal absorption and first-pass hepatic metabolism. Additionally, gastrointestinal adverse effects and potential drug interactions via CYP450 enzymes and P-glycoprotein require careful consideration in clinical practice.

Chromium, an essential trace element, is proposed to enhance insulin receptor activity and support the PI3K/Akt signaling cascade, thereby improving cellular glucose uptake. While some randomized controlled trials have demonstrated modest improvements in glycemic control and insulin sensitivity, the overall evidence is more inconsistent compared to vitamin D and berberine. The variability in clinical outcomes is likely attributable to differences in chromium formulation, dosage, and the baseline chromium status of participants. Chromium picolinate is the most commonly used supplemental form, but the absence of standardized biomarkers for assessing chromium deficiency limits the ability to target supplementation effectively. Current evidence suggests that chromium may benefit selected individuals with impaired glucose metabolism or suspected deficiency, but it does not support universal supplementation for all patients with insulin resistance.

The comparative analysis highlights that the three supplements target different components of insulin resistance pathophysiology. Vitamin D primarily regulates insulin sensitivity through receptor-mediated signaling and inflammatory modulation, while berberine exerts pleiotropic effects through AMPK activation and gut microbiota modulation. Chromium acts predominantly by potentiating insulin receptor activity and downstream signaling. The strength of clinical evidence varies among them, with berberine showing moderate to relatively strong support from multiple randomized trials, vitamin D having a strong biological rationale but heterogeneous intervention data, and chromium presenting the greatest uncertainty. This diversity in mechanisms and evidence strength underscores the complexity of managing insulin resistance and the need for a nuanced, individualized approach to nutritional supplementation.

A major finding from the review is that variability in treatment response cannot be explained solely by the supplements themselves. Instead, it reflects substantial biological and methodological heterogeneity across studies, including differences in obesity status, baseline nutritional deficiencies, intervention protocols, and outcome measures. This suggests that a one-size-fits-all approach to supplementation is unlikely to be effective. The evidence increasingly supports a phenotype-oriented strategy, where supplementation is targeted to patients most likely to benefit, such as those with documented micronutrient deficiencies, obesity, prediabetes, or metabolic dysfunction-associated steatotic liver disease. This perspective aligns with the broader shift toward precision nutrition and personalized metabolic medicine, where clinical decisions are guided by individual metabolic characteristics.

Safety profiles are also a critical consideration when integrating these supplements into clinical practice. Vitamin D is generally well-tolerated, though excessive dosing may increase the risk of hypercalcemia. Berberine is associated with mild gastrointestinal effects and potential drug interactions, necessitating caution in patients on multiple medications. Chromium is considered safe at nutritional doses, but long-term safety data and optimal dosing strategies remain uncertain, particularly in patients with renal impairment or polypharmacy. The review emphasizes that these supplements should be viewed as adjuncts to lifestyle modification and evidence-based therapy, not as stand-alone treatments. Careful patient selection and monitoring are essential to maximize benefits while minimizing potential risks.

The study concludes that future research must focus on adequately powered randomized controlled trials that employ standardized formulations and phenotype-specific patient stratification. Such studies are necessary to clarify the long-term efficacy, safety, and precise role of these supplements in personalized metabolic management. By integrating nutritional supplementation into routine clinical assessment, clinicians can better identify patients who are likely to respond to targeted interventions. This approach may improve therapeutic effectiveness while avoiding unnecessary treatment in individuals unlikely to benefit. Ultimately, the management of insulin resistance requires a comprehensive strategy centered on lifestyle optimization, weight control, and regular physical activity, with complementary nutritional supplementation serving as a supportive element in a broader, patient-centered therapeutic plan.

Subject of Research: Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium

Article Title: Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium

Article References: Todorova, G., Gesheva, T., Boycheva, N., & Mihaylova, A. (2026). Complementary nutritional supplementation in insulin resistance: The role of vitamin D, berberine and chromium. Pharmacia, 73, Article e207685. https://doi.org/10.3897/pharmacia.73.e207685

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e207685

Keywords: Complementary, nutritional, supplementation, insulin, resistance, role, vitamin, berberine, chromium, scientific research

The clinical urgency is difficult to overstate. H. pylori infects a large proportion of the global population and is firmly linked to chronic active gastritis, peptic ulcer disease, gastric mucosal atrophy, intestinal metaplasia, and gastric adenocarcinoma. Prospective cohort evidence has connected infection to subsequent gastric cancer development, and meta-analytic data indicate that eradication therapy can reduce cancer risk in appropriate populations. The Kyoto global consensus went so far as to define H. pylori gastritis as an infectious disease that should be diagnosed and treated wherever detected. Yet the therapeutic arsenal is weakening. The Maastricht VI/Florence Consensus Report urges clinicians to tailor regimens to local resistance patterns and prior antibiotic exposure, while the 2024 American College of Gastroenterology guideline now advises against empirical clarithromycin triple therapy unless susceptibility has been confirmed, recommending 14-day optimized bismuth quadruple therapy as the default empirical option when susceptibility is unknown.

Into this resistant landscape, the study’s authors introduce a deliberately small and transparent computational experiment. They selected three targets representing complementary biological functions: H. pylori urease, the nickel-dependent virulence enzyme that allows the bacterium to survive gastric acid by hydrolyzing urea; DNA gyrase subunit A, essential for DNA topology and replication; and shikimate kinase, part of a biosynthetic pathway present in many microorganisms and plants but absent from humans. Crystallographic structures from the Protein Data Bank served for urease (PDB 1E9Y, with its nickel-containing architecture carefully preserved) and shikimate kinase (PDB 1ZUH), while DNA gyrase A was represented by an AlphaFold model because a suitable experimental structure for blind docking was unavailable. Ligands were docked blindly using CB-Dock2, an automated server combining cavity detection with Vina-type scoring, and the resulting poses were inspected in three dimensions and mapped residue-by-residue in two-dimensional diagrams.

The choice of ligands was grounded in prior experimental data rather than computational convenience. Niclosamide, a salicylanilide anthelmintic long used against tapeworms, had already demonstrated striking anti-H. pylori activity in vitro: it inhibited strain 60190 with a minimum inhibitory concentration of 0.25 micrograms per milliliter, remained active at acidic pH, showed partial synergy with metronidazole and proton pump inhibitors, reduced bacterial adhesion and invasion of gastric epithelial cells by roughly 3 log CFU, and produced no detectable resistance after prolonged exposure in a Galleria mellonella infection model. Berberine, a quaternary ammonium alkaloid from plants such as Berberis species, carries clinical credentials of its own. A randomized phase IV trial found that a 14-day quadruple regimen containing berberine achieved eradication rates of 90.1 percent by intention-to-treat and 91.3 percent per protocol, non-inferior to a bismuth-containing regimen, and a later meta-analysis reported that adding berberine to standard triple therapy improved eradication with a risk ratio of 1.22.

The docking results positioned both candidates favorably. Against urease, niclosamide and berberine tied for the most negative score at –8.5 kcal/mol, outperforming levofloxacin’s –7.9 kcal/mol. Berberine again led against DNA gyrase A at –8.5 kcal/mol, ahead of niclosamide at –7.8 and levofloxacin at –7.5 kcal/mol. Shikimate kinase proved the least favorable target overall, with berberine at –7.3, levofloxacin at –7.0, and niclosamide at –6.9 kcal/mol. Across all three targets, berberine posted the most negative descriptive mean score at –8.10 ± 0.69 kcal/mol, compared with –7.73 ± 0.80 for niclosamide and –7.47 ± 0.45 for levofloxacin. The authors are categorical that these Vina-type outputs are ranking scores only, not binding free energies or affinity constants; a favorable docked score can occur even for a compound that fails to bind in solution.

Perhaps the most technically instructive finding emerged from the two-dimensional interaction maps: identical scores can mask entirely different binding modes. At urease, where niclosamide and berberine shared the same –8.5 kcal/mol value, their predicted stabilization patterns diverged sharply. Berberine’s pose relied mainly on pi-alkyl, pi-sigma, and hydrophobic contacts with residues including LEU A:13, ALA A:16, VAL A:33, PHE B:441, and TYR A:32, while niclosamide’s pose combined conventional hydrogen bonds with hydrophobic, pi-related, and van der Waals contacts involving VAL B:473, TYR B:475, PRO B:472, and MET A:12. At DNA gyrase A, berberine’s aromatic contacts with PHE A:549 and TYR A:525 drove its top ranking, whereas levofloxacin interacted with ASP A:91, ARG A:95, and GLN A:98, including one unfavorable positive-positive contact. The authors caution, however, that the isolated DNA gyrase A model cannot reproduce the DNA–enzyme–drug ternary complex on which fluoroquinolone pharmacodynamics actually depends.

The ADMET profiling added a sobering pharmacokinetic dimension. All three compounds showed zero Lipinski rule-of-five violations and identical bioavailability scores of 0.55, with high predicted gastrointestinal absorption, but their developability profiles differ meaningfully. Niclosamide’s consensus logP of 3.78 and topological polar surface area of 49.33 square angstroms predict membrane permeability, yet its poor aqueous solubility makes formulation-oriented work essential. Berberine’s permanent quaternary cationic structure, which was preserved in the docking preparation, is associated with complex, formulation-dependent exposure that demands experimental confirmation. Neither descriptor set, the study emphasizes, constitutes evidence of therapeutic suitability; they flag questions about exposure, solubility, and formulation that only laboratory measurement can resolve.

The methodological self-awareness sets this study apart from much of the computational drug-repurposing literature. The authors explicitly note that no redocking validation, receiver operating characteristic benchmarking, molecular dynamics simulations, or MM/GBSA or MM/PBSA free-energy analyses were performed, meaning pose accuracy and screening enrichment cannot be claimed. Alternative protonation and tautomeric states of the ligands were not systematically enumerated, a constraint that can influence both poses and scores. Thermodynamically, they explain, a docking score approximates none of the free-state, solvation, desolvation, and entropic contributions required for a true binding free energy, and virtual screening workflows carry substantial false-positive rates. With only three ligands and three targets, no inferential statistics were applied; all summaries are purely descriptive of this specific matrix.

The study also situates itself honestly within prior evidence. The docking results neither reproduce niclosamide’s previously observed antibacterial effects nor identify their mechanism; instead they generate a separate, target-oriented hypothesis that urease, gyrase, and shikimate kinase engagement could be tested experimentally. Similarly, the mixed clinical record of berberine—a more recent randomized trial found no clear superiority for berberine-containing triple therapy, and reported MIC values against H. pylori vary widely by strain and method—means the alkaloid should be viewed as a scaffold for mechanistic and formulation-focused testing rather than a docking-supported monotherapy. The shikimate kinase results, with their small score differences, are downgraded to a lower-priority experimental hypothesis despite the target’s theoretical selectivity advantage.

What remains is a deliberately restricted but actionable set of next steps. The authors propose urease inhibition assays as the first priority, followed by broth microdilution or agar-dilution MIC determination against reference and clinical H. pylori strains, checkerboard combination testing with standard antibiotics, cytotoxicity screening on gastric epithelial cell models, and, if justified by results, molecular dynamics and post-docking free-energy analyses. Within this framework, berberine earns the most consistent score pattern, niclosamide remains the clearest repurposing candidate for urease-focused testing given its prior experimental pedigree, and levofloxacin serves its role as a clinically interpretable yardstick. None of these outputs demonstrates binding, enzyme inhibition, bacterial killing, or therapeutic efficacy—but as an exercise in reducing the experimental search space before costly microbiological testing, the study offers a model of how computational prioritization can be conducted with the caveats firmly attached.

Subject of Research: Computational docking and ADMET profiling of niclosamide and berberine against Helicobacter pylori urease, DNA gyrase A, and shikimate kinase

Article Title: Comparative molecular docking and ADMET profiling of niclosamide and berberine against multiple Helicobacter pylori enzymatic targets

Article References: Danila, C., Faur, L., Mocan, L., & Cavalu, D. S. (2026). Comparative molecular docking and ADMET profiling of niclosamide and berberine against multiple Helicobacter pylori enzymatic targets. Pharmacia, 73, Article e212118. https://doi.org/10.3897/pharmacia.73.e212118

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e212118

Keywords: Helicobacter pylori, molecular docking, niclosamide, berberine, levofloxacin, ADMET, drug repurposing, urease, DNA gyrase, shikimate kinase, antimicrobial resistance, in silico screening

The urgency of the work is underscored by the global malaria burden. According to the World Malaria Reports cited by the authors, malaria claimed more than 610,000 lives and caused 282 million cases in 2024, an increase over the 597,000 deaths and 263 million cases recorded in 2023. Decades of gains from the Global Malaria Eradication Program of the 1950s and 1960s have been eroded by parasites resistant to every major drug class, including aminoquinolines, aryl amino alcohols, antifolates, atovaquone and, most alarmingly, the artemisinin derivatives that form the backbone of current frontline therapy. Resistance to artemisinin-based combination therapies, once confined to South Asia, has now emerged in Africa. With no vaccine effective across all age groups, new chemical scaffolds are desperately needed.

Medicinal plants have historically supplied the best antimalarials: quinine from Cinchona bark inspired chloroquine, and artemisinin came from Artemisia annua. Berberine and palmatine, found in plants such as Berberis, Coptis, Tinospora and Argemone species long used against fever and malaria, have documented in vitro antiplasmodial activity, but their development has been hampered by poor bioavailability—and, until now, by a complete lack of knowledge about how they actually kill the parasite. Earlier hypotheses pointed to DNA binding and telomerase inhibition, but the new study shows those mechanisms cannot explain the drugs’ potency: berberine’s telomerase inhibition required concentrations of 75 to 370 micromolar, far above its antiplasmodial IC50 of 2.4 micromolar.

The team, led by Nekpen Erhunse, Prachi Tomar, Dinkar Sahal and Agam Prasad Singh, exploited a striking property of the alkaloids: they are inherently fluorescent. When the researchers incubated parasites with berberine or palmatine and tracked fluorescence over time, they observed a puzzling, time-dependent loss of signal. Within hours, the glowing alkaloids went dark inside the parasite. The team hypothesized that the compounds were being ferried into a compartment containing something that quenches fluorescence—and the prime suspect was heme, the redox-active, fluorescence-quenching molecule released when the parasite digests hemoglobin in its digestive vacuole.

Co-localization experiments using confocal microscopy, with Hoechst 33342 marking DNA and MitoTracker staining mitochondria, initially suggested mitochondrial accumulation of palmatine at high concentrations, echoing berberine’s behavior in mammalian cells. But at biologically relevant doses, a different picture emerged. The key insight came from the parasite’s own drug-resistance machinery. Berberine and palmatine are known substrates of the human P-glycoprotein multidrug transporter, and P. falciparum carries a homologue, Pgh-1—the product of the pfmdr1 gene—embedded in the membrane of the digestive vacuole, where it imports xenobiotics into that compartment.

To test whether Pgh-1 was the gateway, the researchers blocked the transporter with tariquidar, an inhibitor of its ATPase activity, and with verapamil, a competitive inhibitor. When tariquidar was present, the alkaloids retained their fluorescence and remained visible in the parasite’s cytosol; when it was absent, the fluorescence vanished as the compounds entered the digestive vacuole. Verapamil, by contrast, failed to prevent fluorescence loss, consistent with earlier reports that it is a weak Pgh-1 inhibitor. The results indicated that both alkaloids are actively transported into the digestive vacuole by Pgh-1, where free heme quenches their glow.

Molecular docking studies strengthened the case. The team built a homology model of the 1,419-residue Pgh-1 transporter based on the mouse P-glycoprotein structure and validated it by docking ACT-213615, the lead molecule behind the clinical candidate ACT-451840, which is known to interact with Pgh-1. Berberine bound the transporter’s drug pocket—centered on residues Ser1034 and Asn1042 in transmembrane helix 11—with a more favorable docking score of −7.32 kilocalories per mole than palmatine’s −5.93, mirroring the experimental observation that berberine is the better substrate. Notably, the alkaloids bound in a manner comparable to ACT-451840, suggesting shared transport behavior with a clinically validated antimalarial scaffold.

The strain-specific results were particularly striking. Against the chloroquine-sensitive 3D7 strain, berberine and palmatine showed nearly identical IC50 values of 1.24 and 1.02 micromolar. But against the chloroquine-resistant INDO and multidrug-resistant Dd2 strains, the two structural cousins diverged dramatically: berberine became two- to seven-fold more potent, with resistance indices below one, while palmatine lost potency, with resistance indices above two. The authors attribute this partly to copy number—Dd2 carries four copies of pfmdr1 versus one in 3D7—meaning more transporter and more efficient delivery of berberine into the vacuole of resistant parasites. Crucially, berberine shows no cross-resistance with chloroquine, and PfCRT mutations did not diminish its activity, indicating it does not interact with the chloroquine resistance transporter.

Direct biochemical assays then confirmed the lethal mechanism. Spectrofluorimetry showed the alkaloids’ fluorescence increased upon binding hemoglobin but decreased upon binding hemin, free heme. In cultured parasites, the protease inhibitor E64, which blocks hemoglobin degradation and reduces free heme, restored alkaloid fluorescence in a dose-dependent manner. Most tellingly, both alkaloids inhibited hemozoin formation at concentrations essentially identical to those that kill the parasite—the IC50 for heme biocrystallization inhibition was 0.50 micrograms per milliliter for berberine and 0.80 for palmatine, matching their parasite-killing IC50 values of 0.40 and 0.80. When E64 was added to parasite cultures, roughly 28-fold more alkaloid was needed to achieve the same killing, demonstrating that the drugs’ activity depends on the presence of free heme. A bloated food vacuole assay showed that hemoglobin uptake itself was affected only at very high concentrations, five times the lethal dose, pointing to heme detoxification as the primary target.

The findings carry clear design implications. The authors propose that optimized protoberberine analogues should remain good substrates of the parasite’s Pgh-1 while being poor substrates of the human P-glycoprotein, minimizing host toxicity. They also envision an evolutionary trap: if cytosolic targets of the alkaloids can be identified, dual-action analogues could force the parasite into an impossible choice—mutating Pgh-1 to keep the drugs out of its digestive vacuole would starve it of hemoglobin-derived nutrients, while leaving the transporter intact would deliver a heme-toxic payload straight to its stomach. For a parasite that has outmaneuvered every drug class thrown at it, a weapon it must transport into its own killing chamber may prove uniquely difficult to resist.

Subject of Research: Mechanism of antiplasmodial action of the protoberberine alkaloids berberine and palmatine, which enter the Plasmodium falciparum digestive vacuole via PfPgh-1 and inhibit heme biocrystallization

Article Title: Protoberberine alkaloids berberine and palmatine employ PfPgh-1 transporter to enter the digestive vacuole and kill the malaria parasite by inhibiting heme biocrystallization

Article References: Erhunse, N., Tomar, P., Sahal, D., & Singh, A. P. (2026). Protoberberine alkaloids berberine and palmatine employ PfPgh-1 transporter to enter the digestive vacuole and kill the malaria parasite by inhibiting heme biocrystallization. Frontiers in Drug Discovery, 6, Article 1949463. https://doi.org/10.3389/fddsv.2026.1949463

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1949463

Keywords: malaria, Plasmodium falciparum, berberine, palmatine, protoberberine alkaloids, PfPgh-1, pfmdr1, digestive vacuole, hemozoin, heme biocrystallization, antimalarial drug discovery, drug resistance

The team used Illumina next-generation sequencing to profile the fungal internal transcribed spacer 2 (ITS2) region, a molecular barcode widely employed for fungal identification. By targeting this short stretch of ribosomal DNA, the researchers could detect both culturable and non-culturable fungi, capturing species that would never grow on a laboratory plate. The results were striking: across triplicate samples from all six sample types, the sequencing identified 5 phyla, 32 classes, 39 orders, 68 families, 125 genera, and 273 fungal species, including unknown and unidentified taxa. This level of resolution demonstrates how metagenomic approaches can bypass the limitations of traditional microbiology, which has so far recognized only a small fraction of the estimated 5.1 million fungal species on Earth.

What emerged from the data was a clear pattern of dominance. Ascomycota, the largest phylum of fungi, accounted for between 37.47 and 75.84 percent of all fungal reads across every sample, making it the undisputed ruler of the A. mexicana microbiome. Basidiomycota followed at 3.53 to 6.95 percent, with Zygomycota and unknown taxa rounding out the community. This dominance is not merely a numerical curiosity. Members of Ascomycota are prolific producers of pharmaceutical and commercially important secondary metabolites, including lipases, statins, probiotics, and compounds with antioxidant, antidiabetic, antimicrobial, anticancer, antiviral, and antiprotozoal activities. Their prevalence inside and around A. mexicana suggests they may be intimately involved in the plant’s chemical economy.

The geographic dimension of the study proved equally compelling. Samples from Dergaon consistently showed higher fungal richness than those from Amlighat, as measured by the number of operational taxonomic units (OTUs), the Chao1 index, and phylogenetic diversity. The rhizospheric soil samples were the most diverse of all, with Dergaon soil yielding 2,413.33 OTUs and a Shannon diversity index of 5.84, compared with 2,310 OTUs and 5.65 in Amlighat soil. Roots and shoots harbored far fewer taxa, indicating that the soil environment contains a wide and complex microbial composition that makes it easier for fungi to colonize the roots and then move into the plant’s phyllosphere. These findings align with previous research showing that fungal community structure and function depend heavily on rhizospheric conditions.

Beta diversity analyses, including principal component analysis, hierarchical clustering, UPGMA trees, and network co-occurrence analysis, revealed that the fungal communities of the two locations were mostly similar in composition but differed in relative abundance. Shoots from Amlighat and Dergaon clustered together, as did roots and rhizospheric soils, suggesting that the plant compartment, rather than geography, is the primary driver of community structure. Yet the network analysis showed that the complexity of fungal interactions was highest in the rhizospheric samples, as indicated by the greatest number of nodes and edges, reinforcing the idea that soil is the richest reservoir of fungal diversity feeding into the plant.

Among the genera detected, Meyerozyma was the most abundant across all samples, with relative abundances ranging from 10.46 to 25.06 percent. Ceratocystis, Ganoderma, Cladosporium, Fusarium, and Penicillium were also present in varying amounts. But the most intriguing finding was the consistent presence of Trichoderma species in every single sample, albeit at different relative abundances. This genus is famous in agricultural science as a biocontrol agent and plant growth promoter, and previous work by Verma and colleagues showed that Trichoderma can alter the production of sanguinarine, an acaricidal alkaloid, in Papaver somniferum, the opium poppy. Because P. somniferum and A. mexicana belong to the same family, Papaveraceae, and both produce sanguinarine, the researchers propose that Trichoderma may similarly modulate acaricide production in A. mexicana.

The connection to acaricidal activity is not speculative. An earlier collaborative study by Upadhaya and colleagues tested A. mexicana extracts from the same two locations against ticks and found dramatic differences. Samples from Amlighat killed 80 to 100 percent of ticks, with a mean mortality of 95.0 percent, while samples from Dergaon achieved only 10 to 40 percent mortality, with a mean of 25.0 percent. The current metagenomic data suggest that these differences in tick-killing power may be linked to the distinct fungal communities harbored by plants from each location. Variations in the relative abundance of Trichoderma and other fungi could influence the biosynthesis or accumulation of berberine and sanguinarine, the two acaricidal compounds known from A. mexicana.

The technical rigor of the study deserves attention. The researchers collected roots, shoots, and rhizospheric soil from healthy flowering plants at three sites per location, storing fresh samples in liquid nitrogen. Metagenomic DNA was isolated using the Qiagen DNeasy Power Soil kit for soil and the CTAB method for plant tissues. The ITS2 region was amplified with universal primers ITS3F and ITS4R, producing approximately 250-base-pair amplicons that were used to construct DNA libraries with the NEB Next Ultra kit. Sequencing was performed on an Illumina HiSeq 2500 with 2 × 250-cycle chemistry. Quality control involved removing adapter dimers, eliminating reads with Phred scores below Q30, and deleting reads with more than 5 percent ambiguous bases. Over 80 percent of total reads exhibited Phred scores greater than 30, implying a base call accuracy above 99.9 percent. Taxonomy was assigned using the Ribosomal Database Project classifier against the UNITE fungal reference database, and statistical significance was assessed with ANOVA at p < 0.05.

The broader implications of this work extend beyond a single weed. The northeastern region of India is considered a biodiversity hotspot, yet its microbial diversity remains largely unexplored. By demonstrating that fungal communities associated with a medicinal plant vary between locations and may influence the production of bioactive compounds, the study opens a new frontier in understanding how plant microbiomes shape phytochemistry. If Trichoderma and other fungi can modulate the accumulation of acaricidal alkaloids, then managing the plant microbiome could become a strategy for enhancing the medicinal value of crops and wild plants alike. The findings also underscore the importance of preserving the microbial diversity of biodiversity hotspots, as these hidden communities may hold untapped pharmaceutical potential.

As the researchers conclude, the fungal communities associated with A. mexicana roots, shoots, and rhizospheric soil were identified for the first time in the northeastern region of India using next-generation sequencing. Every sample contained Trichoderma species, and Ascomycota dominated across all compartments. The plant’s pharmaceutically important secondary metabolites, including sanguinarine, berberine, jatrorrhizine, protopine, and columbamine, may be shaped by the fungi that live with it. This revelation transforms our view of a common weed from a simple botanical entity into a complex holobiont, where plant and fungus collaborate in ways that science is only beginning to decipher. The next chapter in this story will likely involve controlled experiments to confirm whether specific fungal species can enhance or suppress the production of tick-killing compounds, potentially leading to microbiome-based approaches for tick management in livestock systems.

Subject of Research: Fungal microbiome diversity and Trichoderma ubiquity in Argemone mexicana across Assam, India

Article Title: Dominance of ascomycota and ubiquity of Trichoderma in Argemone mexicana microbiomes across Assam, India

Article References: Singh, P., Sharma, A., Kumar Sarmah, B., Arivaradarajan, P., Nath, T., & Nandi, S. P. (2026). Dominance of ascomycota and ubiquity of Trichoderma in Argemone mexicana microbiomes across Assam, India. Frontiers in Fungal Biology, 7, Article 1868321. https://doi.org/10.3389/ffunb.2026.1868321

Image Credits: AI Generated

DOI: 10.3389/ffunb.2026.1868321

Keywords: Argemone mexicana, Ascomycota, Trichoderma, metagenomics, fungal diversity, rhizosphere, endophytes, Assam, acaricidal compounds, sanguinarine, berberine, ITS2 sequencing

Polyendocrine metabolic ovarian syndrome affects up to ten percent of women of reproductive age worldwide. It is defined by a triad of hyperandrogenism, chronic anovulation, and polycystic ovarian morphology, and it carries substantial metabolic baggage: insulin resistance, dyslipidemia, and elevated lifetime risks of type 2 diabetes and cardiovascular disease. First-line management currently rests on lifestyle modification and drugs such as metformin, but these options are often limited by modest efficacy, gastrointestinal side effects, and poor long-term adherence. Into this therapeutic gap stepped berberine, an isoquinoline alkaloid extracted from plants such as Berberis vulgaris, which laboratory and early clinical work suggested could sensitize insulin signaling, regulate lipids, and modulate endocrine pathways, all with reportedly fewer gastrointestinal complaints than metformin.

Previous systematic reviews and meta-analyses had indeed painted an encouraging picture, suggesting that berberine could match or even exceed metformin’s effects on metabolic and hormonal outcomes in affected women. But those syntheses rested on a small number of trials, and the field of natural and integrative medicine has faced mounting concerns about methodological rigor, selective reporting, and outright research misconduct. Herbal and nutrient-based interventions, often studied in small trials with limited oversight, have proven particularly vulnerable. The new review therefore took an unusual and increasingly influential approach: rather than assessing only whether the trials were biased in the conventional sense, the researchers formally evaluated whether the trials themselves could be believed at all.

The team conducted their review according to PRISMA guidelines and prospectively registered the protocol in PROSPERO. They searched MEDLINE, EMBASE, the Cochrane Library, and CINAHL from inception through October 2025, looking for randomized controlled trials of berberine supplementation in women with the syndrome. The search yielded 417 records, from which four trials, encompassing a total of 452 participants, met the eligibility criteria. Two came from China, one from India, and one from Pakistan, with sample sizes ranging from 89 to 129 women. Daily berberine or berberine phytosome doses of one to one and a half grams were administered for twelve weeks, compared against metformin, placebo, myo-inositol, or lifestyle interventions, with metabolic, hormonal, and anthropometric outcomes measured throughout.

The critical step came next. Two authors independently assessed each trial’s integrity using two validated frameworks: the Research Integrity in Guidelines and Evidence Synthesis framework, known as RIGID, and the Trustworthiness in Randomised Controlled Trials checklist, known as TRACT. These tools evaluate governance, authorship, intervention plausibility, trial timelines, reporting practices, and the possibility of duplicated data. The verdict was unanimous and stark. All four trials were rated at high risk of compromised integrity. The specific concerns included absent trial registration, which makes it impossible to verify that outcomes and methods were pre-specified and opens the door to selective reporting or post hoc outcome switching; implausibly rapid recruitment timelines that raise the specter of fraudulent or inaccurately reported data; small author groups that undermine accountability and transparency; and potential duplication of data across publications, which can artificially inflate the apparent strength of the evidence base in meta-analyses.

Following the pre-defined RIGID process, the reviewers contacted the authors of the flagged trials to seek clarification of the identified concerns. No responses were received. Under the framework’s rules, trials with high integrity risk and no author response are considered to carry major unresolved concerns and are excluded from all analyses. Because only four eligible trials existed in total, a meaningful sensitivity analysis was impossible, and the entire quantitative synthesis collapsed. The trials had reported consistent improvements in insulin resistance, lipid profiles, and androgen markers, the very outcomes that made berberine famous, but the review team concluded that such findings cannot be considered reliable given the integrity failures. Notably, the researchers assessed risk of bias and research integrity as separate processes, and no study was excluded on the basis of risk of bias alone; the exclusions rested entirely on the integrity assessment.

The implications ripple outward. Because the previous positive systematic reviews appear to have drawn on the same four trials now shown to be at high risk of compromised integrity, the validity of their optimistic conclusions must be reinterpreted with considerable caution. In effect, the entire published case for berberine in this condition rests on a foundation of studies whose authenticity cannot be verified. The review’s authors also point to a parallel effort: their recent meta-analysis of inositol for the syndrome, which informed the 2023 International PCOS Guideline, assessed 43 eligible trials for integrity and excluded them all after the authors failed to respond to queries. That pattern, they argue, reveals a systemic integrity problem across nutrient-supplement research in this field, not an isolated anomaly confined to a single compound.

The clinical consequences are immediate. The authors state plainly that berberine cannot currently be recommended for the management of polyendocrine metabolic ovarian syndrome. This matters all the more because berberine and other vitamins and supplements are widely used among women with the condition, frequently without clinicians’ knowledge. Surveys of clinical practice suggest that clinicians do not routinely ask about supplement use, and patients often do not volunteer it, even though such use can influence reported metabolic and hormonal outcomes and complicate the interpretation of standard treatments. The review’s authors therefore recommend that clinicians proactively and routinely ask women with the syndrome about their supplement intake, including berberine, and factor that information into their interpretation of clinical results until reliable evidence of efficacy and safety exists.

The review does carry limitations of its own. The authors searched only English-language publications due to resource constraints, which means trials published in other languages could exist outside their net. The four eligible trials also suffered from conventional methodological weaknesses beyond the integrity concerns, including small sample sizes, short twelve-week follow-up periods, open-label designs, and heterogeneity in the berberine formulations used, with some preparations lacking a manufacturer-guaranteed concentration of active compound. But these limitations only compound the central problem: a thin evidence base built from trials that cannot be trusted is, for practical purposes, no evidence base at all.

Looking forward, the researchers call for a new generation of high-quality, prospectively registered, placebo-controlled randomized trials with transparent reporting and rigorous methodology to determine whether berberine genuinely holds therapeutic potential for the syndrome, and to establish optimal dosing and long-term safety. They also urge future evidence syntheses to routinely incorporate integrity assessments using frameworks such as RIGID and TRACT, so that clinical guidelines are built only on studies meeting minimal standards of research authenticity and ethical conduct. Until such trustworthy trials arrive, the authors advise that any clinical use of berberine be guided by caution, shared decision-making between patients and clinicians, and ongoing oversight. For the millions of women who have turned to this supplement in hopes of a gentler alternative to prescription drugs, the message is sobering: the science supporting it was never as solid as it seemed.

Subject of Research: Research integrity assessment of berberine trials for polyendocrine metabolic ovarian syndrome

Article Title: Questionable Evidence for Berberine in Polyendocrine Metabolic Ovarian Syndrome: An Integrity-Based Reappraisal

Article References: Perera, E., Mantzioris, E., Moran, L., Scannell, N., Villani, A., Rao, V., Mousa, A., Flannagan, M., & Ee, C. (2026). Questionable Evidence for Berberine in Polyendocrine Metabolic Ovarian Syndrome: An Integrity-Based Reappraisal. Advances in Therapy. https://doi.org/10.1007/s12325-026-03799-7

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03799-7

Keywords: berberine, polyendocrine metabolic ovarian syndrome, polycystic ovary syndrome, research integrity, systematic review, RIGID framework, TRACT checklist, metformin, dietary supplements, randomized controlled trials, insulin resistance, evidence synthesis

TGF-β sits at the heart of the body’s wound-healing machinery, and ionizing radiation hijacks that machinery in a destructive way. When tissue is irradiated, reactive oxygen species are generated that can directly activate latent TGF-β stored in the extracellular matrix, converting the inactive precursor into its potent signaling form. Decades of experimental work, including studies in irradiated murine mammary gland and lung, have shown that TGF-β levels rise in a dose-dependent fashion after thoracic irradiation and correlate with the later development of pulmonary fibrosis. Once activated, the cytokine binds to cell-surface receptors and triggers the phosphorylation of Smad2 and Smad3 proteins, which then translocate into the nucleus to reprogram gene expression toward collagen production, matrix remodeling, and inflammatory signaling.

The pathological consequences of this cascade are well characterized. TGF-β drives the transition of resident fibroblasts into myofibroblasts, the contractile cells that churn out excessive extracellular matrix and deposit collagen throughout the injured tissue. It also promotes epithelial-mesenchymal transition, a process in which epithelial cells lose their normal identity and acquire invasive, matrix-producing characteristics, further amplifying the fibrotic response. In addition, the pathway engages non-canonical branches, including the MAPK and PI3K/Akt cascades, which cross-talk with the Smad system and reinforce inflammation, cell survival, and matrix deposition. Because TGF-β is also implicated in tumor progression and immunosuppression, modulating this axis is a delicate balancing act for any therapeutic strategy aimed at protecting normal tissue during cancer treatment.

Enter the phytochemicals. The review, led by Pouya Goleij and colleagues with contributions from researchers across Iran, the United States, Saudi Arabia, and South Korea, surveys a diverse group of plant-derived molecules with reported multi-target effects on TGF-β signaling. The roster includes curcumin from turmeric, resveratrol from grapes, epigallocatechin gallate (EGCG) from green tea, quercetin from many fruits and vegetables, berberine from barberry, honokiol from magnolia bark, and silibinin from milk thistle. Each of these compounds has been studied extensively in preclinical models of fibrosis, and each appears to converge, by one route or another, on the TGF-β axis.

The mechanistic details vary by compound but share recurring themes. Curcumin has been shown to inhibit Smad signaling in kidney epithelial cells, to downregulate the TGF-β/Smad2/3 pathway in thyroid carcinoma cells, and to block the differentiation of lung fibroblasts into myofibroblasts, in part through activation of the nuclear receptor PPARγ. EGCG appears to interact directly with the TGF-β type II receptor, suppressing signaling at the receptor level, and has been reported to block TGF-β1/Smad-driven epithelial-mesenchymal transition in cancer cells. Quercetin suppresses TGF-β/Smad signaling in keloid-derived fibroblasts and blocks the TGF-β1/PI3K/AKT pathway in models of peritoneal adhesions. Berberine engages the TGF-β receptor itself and attenuates fibrosis through AMPK-mediated inhibition of TGF-β1/Smad signaling. Honokiol and silibinin likewise dampen Smad2/3 phosphorylation and reduce matrix protein expression in lung, renal, and skin fibrosis models.

What makes these findings particularly relevant to radiotherapy is that several of the compounds have now been tested in radiation-specific settings, not merely in chemically induced fibrosis. Curcumin attenuated radiation-induced inflammation and fibrosis in rat lungs, and liposomal curcumin inhibited radiation pneumonitis while sensitizing lung tumors to radiation, an encouraging combination of normal tissue protection and tumor control. Quercetin inhibited radiation-induced skin fibrosis in animal models and, delivered in liposomes, protected against radiation-induced pulmonary injury. EGCG inhibited irradiation-induced pulmonary fibrosis in adult rats and protected intestinal epithelial cells from ionizing radiation in vitro and in vivo. Resveratrol, combined with alpha-lipoic acid, mitigated radiation-induced pneumonitis and lung fibrosis in experimental studies. Berberine has been evaluated for radiation-induced skin injury using proteomic and network pharmacology approaches, and silibinin protected normal lung tissue against radiation injury without reducing the therapeutic efficacy of radiotherapy against lung cancer in preclinical work.

The review is careful to flag a major caveat: most of the mechanistic evidence for these compounds derives from non-radiation fibrosis models, such as those induced by bleomycin, carbon tetrachloride, or silica. While those models share downstream fibrotic pathways with radiation injury, the initiating events differ, and the redox-driven activation of latent TGF-β that is characteristic of irradiated tissue may not be fully recapitulated. Direct validation in radiation-specific models is therefore essential before the preclinical promise can be considered firmly established. The authors also note complexity in the biology itself, as resveratrol has been reported to exert dose-dependent anti-fibrotic or even pro-fibrotic effects in the kidney, a reminder that phytochemicals are not uniformly protective and that dose, context, and tissue type all matter.

Early clinical signals exist but remain preliminary. A randomized, double-blind, placebo-controlled trial of curcumin in thirty breast cancer patients reported reduced severity of radiation dermatitis, and a pilot trial suggested radioprotective effects of curcumin supplementation in prostate cancer patients. Oral nanomicelle curcumin was evaluated for preventing radiotherapy-induced mucositis in head and neck cancer patients, and a combination antioxidant formulation including resveratrol showed protective effects against skin toxicity in breast radiotherapy. EGCG has been tested in a prospective three-arm randomized trial for preventing radiation-induced esophagitis in lung cancer patients and in a phase 2 double-blind, placebo-controlled trial for preventing dermatitis in breast cancer patients receiving postoperative radiotherapy. These studies are mostly small-scale and, in some cases, uncontrolled, and the review emphasizes that their findings require confirmation in larger, adequately powered, well-designed clinical trials before any firm claims of benefit can be made.

Several outstanding questions will shape the field’s next steps. The most critical concern is whether dampening TGF-β signaling in patients undergoing radiotherapy might inadvertently compromise tumor control, given the pathway’s established roles in cancer progression, immune evasion, and resistance to therapy; silibinin’s preclinical profile, which protected normal lung without reducing therapeutic efficacy, offers a template for the kind of evidence that will be needed. Pharmacokinetics pose another hurdle, as compounds like curcumin and resveratrol have notoriously low bioavailability, which has driven interest in nano-enabled and liposomal delivery systems, such as the nano-formulated EGCG that ameliorated silica-induced pulmonary fibrosis in rats. Safety in patients with impaired organ function, the possibility of paradoxical pro-fibrotic effects at certain doses, and the challenge of timing interventions relative to the course of radiotherapy all remain open. Still, the convergence of mechanistic plausibility, multi-target preclinical activity, and early human signals positions these plant-derived molecules as credible candidates for supportive strategies against radiation-induced normal tissue injury, pending the rigorous clinical validation that the review’s authors rightly demand.

Subject of Research: Phytochemical modulation of TGF-β signaling in radiation-induced fibrosis

Article Title: Phytochemicals modulating TGF-β signaling in radiation-induced fibrosis

Article References: Goleij, P., Mirzaei, M., Babamohamadi, M., Sadreddini, S., Abolfazli, S., Tabari, M. A. K., Movafagh, A., Aschner, M., & Khan, H. (2026). Phytochemicals modulating TGF-β signaling in radiation-induced fibrosis. Molecular Biology Reports, 53(1), Article 1653. https://doi.org/10.1007/s11033-026-12867-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12867-8

Keywords: TGF-β signaling, radiation-induced fibrosis, phytochemicals, curcumin, resveratrol, EGCG, quercetin, berberine, Smad pathway, radiotherapy, fibrosis, radioprotection

The review, led by Caiyan Wang and Zhongqiu Liu of Guangzhou University of Chinese Medicine together with colleagues, synthesizes how high-resolution structural biology, computational chemistry and artificial intelligence are being combined to dissect multi-component synergy at atomic resolution. The stakes are considerable. Artemisinin-based combination therapies alone benefit more than 200 million malaria patients annually, and the World Health Organization credits such treatments with helping drive malaria deaths down from 736,000 in 2000 to 409,000 in 2019. But those successes came from isolating single active molecules, a reductionist strategy that, by its very triumph, exposed the limits of the single-component, single-target paradigm when applied to whole herbal formulations.

The core methodological insight of the new field is that two complementary approaches, long pursued separately, can be chained together into a closed loop of prediction and validation. Network pharmacology, which mines databases such as BATMAN-TCM to map relationships between herbal ingredients, protein targets and diseases, excels at generating holistic, top-down hypotheses about which components might matter. What it cannot do is explain how those interactions physically occur. Structural pharmacology supplies the bottom-up counterpart: X-ray crystallography, cryo-electron microscopy and nuclear magnetic resonance spectroscopy resolve the three-dimensional geometry of drug-target complexes, while molecular docking and molecular dynamics simulations trace how binding events unfold in time. In the authors’ metaphor, network pharmacology draws the roadmap; structural biology validates the key junctions on it.

The power of this pipeline is illustrated by work on Huashi Baidu Formula, a traditional prescription analyzed for activity against SARS-CoV-2. Researchers first used ultra-performance liquid chromatography coupled with mass spectrometry to catalog 343 distinct chemical constituents in the formula, then identified 60 prototype compounds and 66 metabolites that were actually absorbed into the body. From that pool, six bioactive constituents, including magnolol, emodin and quercetin, showed synergistic antiviral effects through distinct target engagement. Structural analysis revealed a division of labor: quercetin and licochalcone A inhibit the virus’s main protease, while neoglycyrol and glycyrol A target the RNA-dependent RNA polymerase and additionally occupy the catalytic site of phosphodiesterase 4, an inflammatory enzyme. One formula, several molecules, several targets, one coordinated outcome.

The review goes further, arguing that even the ancient doctrine of Jun-Chen-Zuo-Shi, the sovereign-minister-assistant-envoy principle that governs how herbs are combined in a prescription, can now be mapped onto concrete molecular mechanisms. The test case is Compound Huangdai Tablet, used to treat acute promyelocytic leukemia. Tetrasodium arsenic tetrasulfide, the sovereign component, forms covalent bonds with cysteine residues of the disease-causing PML-RARα fusion protein, acting as a molecular clamp that flags the oncoprotein for degradation. Indirubin, the minister, stabilizes the arsenic compound and independently slots into the ATP-binding pocket of CDK6, boosting cell-cycle arrest efficiency 3.7-fold. Tanshinone IIA, the assistant, activates antioxidant Nrf2 signaling and cuts reactive oxygen species by 63 percent, tempering toxicity, while a polysaccharide from Pseudostellaria heterophylla, the envoy, enhances drug accumulation in bone marrow 2.8-fold. Each classical role acquires a measurable structural basis.

Underpinning these stories is a revolution in how protein structures are captured. X-ray crystallography, the workhorse of structural biology, delivered a 1.8-angstrom structure of shikonin, a naphthoquinone from a traditional antiviral herb, bound to the SARS-CoV-2 main protease, revealing how the molecule’s ring system stacks against the catalytic dyad while its side chain threads through three substrate pockets. Cryo-electron microscopy, which images flash-frozen molecules without crystallization, has resolved the double-arrowed tetrameric architecture of ATP-citrate lyase and shown how puerarin stabilizes a desensitized state of the GABAA receptor through π-π stacking and hydrogen bonding. An emerging technique called microcrystal electron diffraction goes further still, extracting atomic structures from nanogram quantities of material and crystals as small as 50 nanometers, small enough to solve the structure of a fungal natural product directly from crude extract without purification.

Artificial intelligence is accelerating every stage of this workflow. The TCMBank database developed at Peking University now catalogs 9,192 herbs, 61,000 ingredients and 15,000 targets, providing the raw material for deep-learning models that predict drug-target affinity and synergy. In one demonstration, a combined protocol of molecular docking, a hybrid neural network and 50-nanosecond dynamics simulations revealed that soy cerebrosides in the formula Wen-Gao-Tang block LDL uptake by binding the low-density lipoprotein receptor, an effect that synergizes with curcumin’s inhibition of HIF-1α; cell experiments confirmed a 42 percent reduction in the inflammatory cytokine IL-6. In another case, a fine-tuned language model trained on 68,654 prescriptions predicted seven triterpenoid modification sites in Ganoderma spore powder that improved intestinal permeability, and reformulation raised the compounds’ in vivo exposure 2.3-fold while cutting production time by 30 percent.

Yet the review is candid about the bottlenecks. Only about 30 percent of known active ingredients in existing databases have resolvable three-dimensional target information, leaving most herbal molecules without mechanistic annotation. More fundamentally, proteins are not static sculptures. Many disease-relevant conformational changes, such as the millisecond flips of the KRAS Switch-II region or the transitions of amyloid peptides from helical monomers to toxic oligomers, happen too fast and too weakly for conventional crystallography or even cryo-EM snapshots to register. Herbal components frequently bind through transient, micromolar-affinity interactions dominated by hydrophobic contacts and hydrogen bonds, precisely the events that surface plasmon resonance and isothermal titration calorimetry struggle to capture. Data standardization compounds the problem: batch-to-batch variation in herbs and inconsistent experimental parameters weaken the generalization of AI models trained on them.

The proposed remedies are as ambitious as the problems. Time-resolved serial femtosecond crystallography at X-ray free-electron lasers can film conformational changes from femtoseconds to minutes, using pulses so brief that diffraction is recorded before radiation damage destroys the sample. Organoid and single-cell technologies add physiological context, allowing researchers to track which cell subtypes, such as CYP3A4-high liver cells that are more susceptible to artemisinin derivatives, actually metabolize herbal compounds. Light-sheet fluorescence microscopy has visualized the shuttle of paeoniflorin between lysosomes and mitochondria at 50-nanometer resolution and 30 frames per second, offering direct visual evidence for the sovereign-minister-assistant-envoy theory in action. The authors propose integrating such real-time conformational data into a next-generation database that could raise three-dimensional target coverage from roughly 30 percent to more than 60 percent.

If the vision holds, the implications extend well beyond validating tradition. A structural, predictive framework for multi-component synergy would give drug developers a systematic way to design combination therapies that exploit cooperative binding, allosteric communication and complementary target engagement, principles that conventional single-molecule pipelines rarely exploit. It would also provide the evidentiary foundation regulators and international standards bodies need to evaluate complex herbal products. The authors frame the trajectory as a shift from empirical induction to dynamic design: from asking whether an ancient formula works, to knowing exactly which molecule binds which protein, in which conformational state, and why the combination outperforms its parts. For a pharmacopoeia built over two millennia, that would amount to the most rigorous translation it has ever received.

Subject of Research: Structural pharmacology approaches for decoding multi-component, multi-target synergy mechanisms in traditional Chinese medicine

Article Title: Structural pharmacology of Chinese medicine: technological breakthroughs in decoding multi-target synergy and precision mechanisms

Article References: Wang, C., Li, Y., Zhuo, L., Xu, S., Wang, M., & Liu, Z. (2026). Structural pharmacology of Chinese medicine: technological breakthroughs in decoding multi-target synergy and precision mechanisms. Advanced Biotechnology, 4(1), Article 11. https://doi.org/10.1007/s44307-026-00095-x

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00095-x

Keywords: traditional Chinese medicine, structural biology, cryo-electron microscopy, molecular docking, network pharmacology, artificial intelligence, multi-target synergy, X-ray crystallography, drug discovery, berberine, artemisinin, precision medicine

The researchers set out to answer a question that has shadowed addiction neuroscience for decades: what allows drugs to drive dopamine release at intensities that ordinary rewards never reach? Their hypothesis centered on energy. Dopamine terminals in the nucleus accumbens are extraordinarily metabolically demanding structures, packed with mitochondria positioned near active zones where vesicles of dopamine await release signals. When dopaminergic neurons fire at high frequency, the energy demands of packaging, mobilizing, and releasing vesicles can outstrip local ATP supplies. Previous work had established that presynaptic mitochondria buffer calcium and synthesize ATP on demand, but whether this mitochondrial machinery was specifically recruited during drug reward—rather than reward in general—remained unknown.

To watch mitochondrial calcium in real time, the team used a genetically encoded fluorescent indicator called 4mt-jGCaMP8s, targeted to the mitochondrial matrix, expressed selectively in dopaminergic neurons of mice. Using fiber photometry, they monitored calcium signals from dopaminergic terminals in the nucleus accumbens while animals received heroin, morphine, methamphetamine, or cocaine. The results were unambiguous: heroin and methamphetamine produced robust, rapid mitochondrial calcium transients in accumbal dopamine terminals, while cocaine did not. This selectivity held up under two-photon imaging with a head-mounted microscope in freely moving animals, and the signal was strongest in the core of the nucleus accumbens, a subregion closely tied to drug seeking. Critically, when animals consumed natural rewards such as sucrose, the same terminals showed no comparable mitochondrial calcium influx.

The gateway for this calcium was identified as the mitochondrial calcium uniporter, or MCU, a channel in the inner mitochondrial membrane that was molecularly identified more than a decade ago. MCU allows calcium to flow down its steep concentration gradient into the mitochondrial matrix, where it activates calcium-sensitive enzymes of the tricarboxylic acid cycle and stimulates oxidative phosphorylation. In essence, mitochondrial calcium influx is how a mitochondrion learns that its host cell is working hard and needs more fuel. The Beijing team confirmed that the drug-evoked signals depended on MCU: in dopaminergic neurons lacking the uniporter, or in neurons treated with the MCU inhibitors Ru360 and berberine, the drug-induced mitochondrial calcium rise was abolished, while cytoplasmic calcium responses to the drugs remained intact.

Why would drugs, but not natural rewards, engage this pathway? The answer emerged from optogenetic experiments in which the researchers artificially drove dopaminergic terminals at defined frequencies. At low stimulation frequencies of around 4 hertz, mimicking the modest firing rates associated with physiological rewards, mitochondrial calcium barely moved, and deleting MCU had no effect on evoked dopamine release. But at 20 and 40 hertz—intensities characteristic of drug-evoked activation—mitochondrial calcium influx became prominent, and its absence sharply reduced dopamine release measured with the GRAB_DA2m fluorescent sensor. The conclusion is elegant: MCU-mediated mitochondrial calcium is recruited only when dopaminergic neurons are pushed beyond their normal metabolic comfort zone, which is precisely the regime that addictive drugs occupy and that natural rewards do not.

The mechanism linking calcium to release proved to be energy. Using the genetically encoded ATP sensor ATeam1.03 targeted to mitochondria, the researchers showed that drug-like high-intensity stimulation drove a rapid rise in mitochondrial ATP production that required MCU. When they blocked ATP synthesis with oligomycin, or supplied exogenous ATP to neurons lacking MCU, the picture sharpened further: ATP replenishment rescued the vesicle release deficit in MCU-deficient neurons, while ATP depletion mimicked it. Probing the vesicle machinery directly with a pHluorin-tagged vesicular monoamine transporter, the team found that the readily releasable pool of dopamine vesicles was depleted in MCU knockout neurons, and that this deficit was restored by ATP supplementation. In other words, the mitochondrial calcium influx does not directly trigger release; it manufactures the ATP that keeps the release machinery stocked during metabolically punishing bursts of activity.

The behavioral consequences were decisive. Mice engineered to lack MCU specifically in dopaminergic neurons showed dramatically reduced locomotor responses to heroin and morphine, blunted conditioned place preference for opioids, and diminished cue-induced reinstatement of cocaine seeking after extinction—a laboratory model of relapse. Circuit-specific deletion confirmed the anatomy: removing MCU only from dopaminergic neurons projecting from the ventral tegmental area to the nucleus accumbens impaired heroin reward, whereas deletion in the projection to the prefrontal cortex did not. Pharmacological validation followed. Berberine, a natural compound recently characterized as an MCU inhibitor that disrupts the channel’s assembly with its regulatory partner EMRE, reduced mitochondrial calcium uptake in cultured dopaminergic neurons, attenuated heroin conditioned place preference when microinjected into the nucleus accumbens, and suppressed cue-induced reinstatement of cocaine seeking when given systemically.

Perhaps most striking is what did not happen. Mice lacking MCU in dopaminergic neurons performed indistinguishably from controls across a battery of tests probing dopamine-dependent physiology: spontaneous locomotion, working memory in the Y-maze, anxiety-like behavior, despair-related immobility, sucrose preference, motor coordination on the rotarod, and spatial learning in the Morris water maze. Food-conditioned place preference, a model of natural reward learning, was preserved. Whole-brain MCU knockout mice, generated with Nestin-Cre, developed normally with expected Mendelian ratios and showed no deficits in dopamine-related behaviors. The therapeutic window implied by these results is unusually wide: the bioenergetic pathway appears to be dispensable for everyday reward processing yet essential for the supraphysiological dopamine output that drugs commandeer.

The study reframes addiction as, in part, a metabolic disease of synapses. Drugs of abuse differ in their molecular targets—opioids bind receptors, methamphetamine reverses transporters, cocaine blocks reuptake—but they converge on a common output: high-intensity dopaminergic activation in the accumbens. This work shows that convergence extends to the mitochondria, which are forced into emergency ATP production to sustain the pathological signal. By targeting MCU, or the calcium-driven bioenergetics it enables, it may be possible to starve the addictive circuitry of its energy supply while leaving the mitochondria of ordinary reward signaling untouched. Considerable distance remains between mouse models and human therapy, and berberine’s properties as a drug candidate will need rigorous evaluation. But the identification of a drug-selective mitochondrial mechanism offers something addiction research has rarely possessed: a molecular distinction between the dopamine that fuels compulsion and the dopamine that fuels life.

Subject of Research: Mitochondrial calcium uniporter-mediated bioenergetics in dopaminergic terminals that selectively enable drug-induced dopamine release and addictive behavior

Article Title: Mitochondrial calcium influx-driven bioenergetics selectively enable drug addiction

Article References: Gao, J., Zhao, H., Han, X., Zeng, L., Pan, J., Liu, G., Wei, X., Liu, C., Wu, W., Chen, S., Chen, J., Li, T., Yin, J., Zhou, T., Zhang, X.-M., Li, A.-L., Li, T., & Pan, X. (2026). Mitochondrial calcium influx-driven bioenergetics selectively enable drug addiction. Nature Neuroscience. https://doi.org/10.1038/s41593-026-02421-x

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02421-x

Keywords: addiction, mitochondria, mitochondrial calcium uniporter, dopamine, nucleus accumbens, reward, MCU, bioenergetics, opioids, methamphetamine, ATP, berberine